y t i s 1 0 n e t n M · P r o t e i n ( p g / m L ) M e a n F l u o r e s c e n c e I n t e n s i...
Transcript of y t i s 1 0 n e t n M · P r o t e i n ( p g / m L ) M e a n F l u o r e s c e n c e I n t e n s i...
P r o t e in ( p g / m L )
Me
an
Flu
ore
sc
en
ce
In
te
ns
ity
0 . 1 1 1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
0 . 1
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
1 0 0 0 0 0
P r o t e in ( p g / m L )
Me
an
Flu
ore
sc
en
ce
In
te
ns
ity
0 . 1 1 1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
0 . 1
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
1 0 0 0 0 0
Figure 1. Representative curves for one analyte from a multiplex panel showing the extended ranges of 0.6 to
10,000 pg/mL for mouse IL-13 (left) and 1.5 to 30,000 pg/mL for human TNF alpha (right).
Figure 2. Linearity of dilution in native samples (A) and spike-recovery (B) studies for sTNF RI. Mean recovery
and standard error are plotted. A: Each sample was tested at a 1:4 dilution and at six further dilutions for
serum and plasma and three for other sample types. A two-fold dilution series was used. Analyte
concentrations were interpolated from the standard curve. Percentage recovery is relative to the 1:4 dilution.
B: Three different concentrations of protein standard were spiked into three different sample dilutions. Analyte
concentration was interpolated from the standard curve. Percentage recovery was calculated after
subtraction of the no-spike control value.
1 1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
p g / m L
Me
an
Flu
ore
sc
en
ce
In
te
ns
ity
S t a n d a r d c u r v e
S e r u m
P la s m a ( c i t r a t e )
P l a s m a ( E D T A )
P la s m a ( H e p a r i n )
C u l t u r e s u p e r n a t a n t
1 1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
p g / m L
Me
an
flu
ore
se
nc
e i
nt
en
sit
y
B A L
S y n o v i a l f l u i d
C S F
M i l k ( d e f a t t e d )
S a l i v a
S t a n d a r d c u r v e
1 1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
1 0 0 0 0 0
p g / m l
Me
an
flu
ore
se
nc
e i
nt
en
sit
y
S e r u m
C u l t u r e s u p e r n a t a n t
P la s m a ( c i t r a t e )
P la s m a ( H e p a r i n )
P l a s m a ( E D T A )
S t a n d a r d c u r v e
Figure 3. Confirmation of parallelism using the same data as figure 2 for native linearity of dilution (A and B)
and spike-recovery (C). A: For each sample, analyte concentration in the 1:4 dilution was calculated by
interpolation against the standard curve. The concentration of each subsequent dilution was then calculated
and plotted, based on the dilution factor, from the concentration of the 1:4 dilution. B: The spiked
concentration after non-spike control subtraction is plotted. The range of concentrations tested by spike-
recovery was limited by the level of native protein.
0%
20%
40%
60%
80%
100%
120%
140%
0%
20%
40%
60%
80%
100%
120%
140%
Figure 4. Example of combinatorial testing using unique detector antibody / protein standard
pools. Over the 88 analytes and 3.8x1022 possible custom panels tested, only one combination
(Eotaxin and IP-10) was identified as incompatible. The two tallest bars represent two pools tested
against the IP-10 capture particle; both contain Eotaxin assay components, but have no other
analyte in common.
M o u s e I P - 1 0 ( p g / m L )
Me
an
Flu
ore
sc
en
ce
In
te
ns
ity
1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
I P - 1 0 s in g le p le x
I P - 1 0 m u l t ip l e x
M o u s e C D 3 1 ( p g / m L )
Me
an
Flu
ore
sc
en
ce
In
te
ns
ity
1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
0 . 1
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
C D 3 1 s in g le p l e x
C D 3 1 m u l t i p le x
M o u s e P F 4 ( p g / m L )
Me
an
Flu
ore
sc
en
ce
In
te
ns
ity
1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
P F 4 s in g le p le x
P F 4 m u l t ip l e x
M o u s e L e p t in ( p g / m L )
Me
an
Flu
ore
sc
en
ce
In
te
ns
ity
1 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0
0 . 1
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
L e p t in m u l t ip le x
L e p t in s in g le p le x
Figure 5. Representative examples of standard curve alignment testing in singleplex and in
multiplex. Leptin and PF-4 were tested in an 18 analyte multiplex panel; CD31 and IP-10 in a 15
and 10 analyte panel respectively. Testing of mouse serum samples in the same experiments
resulted in an average CV of 3% between singleplex and multiplex assays.
Figure 6. Seven cytokines were quantified in normal serum and serum from patients with
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and atopic dermatitis (AD). Each dot
represents an individual patient. Data was consistent with relevant publications3-5.
0
100
200
300
400
500
600
Pro
tein
(p
g/m
L)
RASLEAD
TNFα IL-2 IL-4 IL-5 IL-6 IL-10 GM-CSF
Figure 7. Inter-assay CV% values. To determine intra-assay CVs, a single biological sample is
tested at three sample dilutions with four replicates of each dilution. This experiment is performed
three times on different days to determine inter-assay CVs.
Figure 8. SimpleStep ELISA® kits and a FirePlex immunoassay was used to determine human BCA1,
IL-17A, GM-CSF, G-CSF, TARC, IL-10 and RANTES concentrations in supernatant from a PBMC cell
culture which had been stimulated with 1.5% PHA-M for 24 hours.
0
2
4
6
8
10
12
14
CV
%
R² = 0.9841
0
1,000
2,000
3,000
4,000
0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000
Sim
ple
Ste
p E
LISA
(p
g/m
L)
FirePlex immunoassay (pg/mL)
Figure 9. Eleven human cytokines (IFN-gamma, IL-4, IL-1 beta, MCP1, TNF-alpha, IL-10, IL-5, IL-17A,
IL-2, IL-6, IL-12p70) in stimulated PBMC cell culture supernatants were analyzed with both Luminex
assays (Millipore catalog# HCytoMAG-60K, tested by Boston University Analytical Instrumentation
Core) and a FirePlex immunoassay panel.
1
10
100
1000
10000
100000
pg
/mL
Firefly immunoassay
Luminex assay
R² = 0.9659
0
5,000
10,000
15,000
20,000
25,000
30,000
0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000
Fire
fly a
ssa
y (
pg
/mL)
Bead-based (pg/mL)